Abstract
Address: 1Royal Free and University College Medical School, London, UK, 2Copenhagen HIV Programme, Panum Institute, Copenhagen, Denmark, 3Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, Netherlands, 4Istituto Di Clinica Malattie Infettive e Tropicale, Milan, Italy, 5Hospital Clinic i Provincial, Barcelona, Spain, 6Royal Sussex County Hospital, Brighton, UK, 7Medical University, Gdansk, Poland and 8Medical Academy Botkin Hospital, St Petersburg, Russian Federation * Corresponding author
Highlights
Achieving virological suppression in immunocompromised patients is important for reducing the risk of opportunistic infections (OIs)
Patients contributed to the person-years at risk if the most recent CD4 count was ≤200 cells/mm3, and if viral load (VL) was measured in the 6 months before the CD4 count
Multivariable analyses were adjusted for current CD4 count, VL, calendar time of follow-up, age, whether or not ART-naive, ethnicity, risk group, hepatitis B and C status, and for death rates, prior AIDS diagnosis
Summary
WP Bannister*1, A Mocroft, O Kirk, P Reiss, A d'Arminio Monforte, JM Gatell, M Fisher, H Trocha, A Rakhmanova and JD Lundgren. Address: 1Royal Free and University College Medical School, London, UK, 2Copenhagen HIV Programme, Panum Institute, Copenhagen, Denmark, 3Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, Netherlands, 4Istituto Di Clinica Malattie Infettive e Tropicale, Milan, Italy, 5Hospital Clinic i Provincial, Barcelona, Spain, 6Royal Sussex County Hospital, Brighton, UK, 7Medical University, Gdansk, Poland and 8Medical Academy Botkin Hospital, St Petersburg, Russian Federation. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):O36 doi:10.1186/1758-2652-11-S1-O36. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
